Matthew Biegler
Stock Analyst at Oppenheimer
(0.81)
# 3,609
Out of 4,810 analysts
75
Total ratings
23.08%
Success rate
-22.06%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matthew Biegler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VOR Vor Biopharma | Reiterates: Outperform | $8 | $0.70 | +1,042.86% | 7 | Mar 21, 2025 | |
| OLMA Olema Pharmaceuticals | Reiterates: Outperform | $30 → $25 | $4.21 | +493.82% | 5 | Mar 19, 2025 | |
| ARVN Arvinas | Maintains: Outperform | $40 → $45 | $7.58 | +493.67% | 4 | Feb 12, 2025 | |
| GILD Gilead Sciences | Reiterates: Outperform | $105 → $115 | $105.68 | +8.82% | 1 | Dec 10, 2024 | |
| IDYA IDEAYA Biosciences | Reiterates: Outperform | $53 | $16.98 | +212.13% | 5 | Oct 29, 2024 | |
| TYRA Tyra Biosciences | Maintains: Outperform | $25 → $33 | $8.66 | +281.06% | 6 | Sep 19, 2024 | |
| ZNTL Zentalis Pharmaceuticals | Reiterates: Outperform | $20 | $1.27 | +1,474.80% | 7 | Sep 16, 2024 | |
| RLAY Relay Therapeutics | Downgrades: Perform | n/a | $2.76 | - | 6 | Sep 10, 2024 | |
| ORIC ORIC Pharmaceuticals | Maintains: Outperform | $17 → $15 | $5.04 | +197.62% | 4 | Aug 13, 2024 | |
| ALLO Allogene Therapeutics | Assumes: Outperform | $13 → $11 | $1.46 | +653.42% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $114 → $125 | $81.45 | +53.47% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Peer Perform | n/a | $11.97 | - | 4 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $16 → $14 | $3.04 | +360.53% | 5 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $4.98 | - | 1 | Apr 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $1.12 | - | 5 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Perform | n/a | $7.19 | - | 2 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $25 | $2.15 | +1,062.79% | 1 | Jun 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.72 | - | 3 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Perform | n/a | $1.74 | - | 2 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $520 → $360 | $7.99 | +4,405.63% | 1 | Nov 30, 2022 |
Vor Biopharma
Mar 21, 2025
Reiterates: Outperform
Price Target: $8
Current: $0.70
Upside: +1,042.86%
Olema Pharmaceuticals
Mar 19, 2025
Reiterates: Outperform
Price Target: $30 → $25
Current: $4.21
Upside: +493.82%
Arvinas
Feb 12, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $7.58
Upside: +493.67%
Gilead Sciences
Dec 10, 2024
Reiterates: Outperform
Price Target: $105 → $115
Current: $105.68
Upside: +8.82%
IDEAYA Biosciences
Oct 29, 2024
Reiterates: Outperform
Price Target: $53
Current: $16.98
Upside: +212.13%
Tyra Biosciences
Sep 19, 2024
Maintains: Outperform
Price Target: $25 → $33
Current: $8.66
Upside: +281.06%
Zentalis Pharmaceuticals
Sep 16, 2024
Reiterates: Outperform
Price Target: $20
Current: $1.27
Upside: +1,474.80%
Relay Therapeutics
Sep 10, 2024
Downgrades: Perform
Price Target: n/a
Current: $2.76
Upside: -
ORIC Pharmaceuticals
Aug 13, 2024
Maintains: Outperform
Price Target: $17 → $15
Current: $5.04
Upside: +197.62%
Allogene Therapeutics
Aug 8, 2024
Assumes: Outperform
Price Target: $13 → $11
Current: $1.46
Upside: +653.42%
Jul 8, 2024
Maintains: Outperform
Price Target: $114 → $125
Current: $81.45
Upside: +53.47%
Jul 2, 2024
Downgrades: Peer Perform
Price Target: n/a
Current: $11.97
Upside: -
May 14, 2024
Maintains: Outperform
Price Target: $16 → $14
Current: $3.04
Upside: +360.53%
Apr 1, 2024
Reiterates: Perform
Price Target: n/a
Current: $4.98
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $1.12
Upside: -
Feb 27, 2024
Reiterates: Perform
Price Target: n/a
Current: $7.19
Upside: -
Jun 2, 2023
Initiates: Outperform
Price Target: $25
Current: $2.15
Upside: +1,062.79%
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.72
Upside: -
Dec 22, 2022
Downgrades: Perform
Price Target: n/a
Current: $1.74
Upside: -
Nov 30, 2022
Maintains: Outperform
Price Target: $520 → $360
Current: $7.99
Upside: +4,405.63%